Allogeneic hematopoietic stem cell transplantation (SCT) after a patient with acute myeloid
leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with …

Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved
for older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy based …

Approximately 50% of patients with hematologic malignancies relapse after chimeric antigen
receptor (CAR) T cell treatment; mechanisms of failure include loss of CAR T persistence …

Despite the approval of new drugs, the inclusion of-omics-derived data and the integration of
machine learning in both the diagnostic and therapeutic process, the prognosis of acute …

Introduction The BCL-2 inhibitor venetoclax has been widely used in the treatment of acute
myeloid leukemia (AML); however, AML patients treated with venetoclax gradually develop …

Simple Summary The introduction of venetoclax (VEN) to combination regimens has
dramatically changed the paradigm of treatment for acute myeloid leukemia (AML) patients …

Abstract Treatment options for acute myeloid leukemia (AML) have expanded over the last 5
years. New regimens are increasing the options for patients who previously may not have …

目的: 靶向药物BCL-2 抑制剂维奈克拉(venetoclax, VEN) 的出现革新了急性髓系白血病(acute
myeloidleukemia, AML) 的治疗格局, 尤其是对于老年或不适合强化疗的患者 …

Discussion It is well-described that increasing age—and in particular age greater than 60
years old—is a risk factor for poorer response to traditional intensive induction …

In the second act of Shakespeare's Romeo and Juliet, Juliet argues that despite Romeo
being of Montague—and not Capulet—lineage, their burgeoning love affair should be …